Literature DB >> 12843129

Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling?

Ivan V Litvinov1, Angelo M De Marzo, John T Isaacs.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12843129     DOI： 10.1210/jc.2002-022038

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  78 in total

Review 1.  Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.

Authors:  Simeng Wen; Yuanjie Niu; Soo Ok Lee; Chawnshang Chang
Journal:  Cancer Treat Rev       Date:  2013-08-07       Impact factor: 12.111

Review 2.  Stem cells in prostate cancer initiation and progression.

Authors:  Devon A Lawson; Owen N Witte
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

3.  A mathematical investigation of the multiple pathways to recurrent prostate cancer: comparison with experimental data.

Authors:  Trachette L Jackson
Journal:  Neoplasia       Date:  2004 Nov-Dec       Impact factor: 5.715

4.  Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Yi Xu; Lizamma Antony; Susan L Dalrymple; John T Isaacs
Journal:  Cancer Res       Date:  2006-09-01       Impact factor: 12.701

5.  The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells.

Authors:  Anthony J Saporita; Junkui Ai; Zhou Wang
Journal:  Prostate       Date:  2007-04-01       Impact factor: 4.104

6.  CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis.

Authors:  Michael A Augello; Deli Liu; Lesa D Deonarine; Brian D Robinson; Dennis Huang; Suzan Stelloo; Mirjam Blattner; Ashley S Doane; Elissa W P Wong; Yu Chen; Mark A Rubin; Himisha Beltran; Olivier Elemento; Andries M Bergman; Wilbert Zwart; Andrea Sboner; Noah Dephoure; Christopher E Barbieri
Journal:  Cancer Cell       Date:  2019-03-28       Impact factor: 31.743

7.  The role of CD133 in normal human prostate stem cells and malignant cancer-initiating cells.

Authors:  Donald J Vander Griend; Wouter L Karthaus; Susan Dalrymple; Alan Meeker; Angelo M DeMarzo; John T Isaacs
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

8.  Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.

Authors:  Pratap Singh; Gurulingappa Hallur; Ravi K Anchoori; Oladapo Bakare; Yukio Kageyama; Saeed R Khan; John T Isaacs
Journal:  Prostate       Date:  2008-10-01       Impact factor: 4.104

9.  Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis.

Authors:  Bora Gurel; Tsuyoshi Iwata; Cheryl M Koh; Robert B Jenkins; Fusheng Lan; Chi Van Dang; Jessica L Hicks; James Morgan; Toby C Cornish; Siobhan Sutcliffe; William B Isaacs; Jun Luo; Angelo M De Marzo
Journal:  Mod Pathol       Date:  2008-06-20       Impact factor: 7.842

Review 10.  Prostate stem cells and benign prostatic hyperplasia.

Authors:  John T Isaacs
Journal:  Prostate       Date:  2008-06-15       Impact factor: 4.104
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.